[stock_market_widget type=”card” template=”basic2″ assets=”MCRB” realtime=”true” api=”yahoo-finance”]
Live biotherapeutics are emerging as a new class of medicines built from living microbes, developed and regulated more like drugs than dietary supplements. Unlike over-the-counter probiotics, these therapies use defined bacterial strains at controlled doses and are tested in clinical trials for specific medical conditions. Their goal is to harness the interaction between gut bacteria, the immune system, and the intestinal barrier—systems that play a critical role in how the body responds to disease and modern treatments, including cancer immunotherapy.
At the center of this approach is the concept of dysbiosis, or imbalance in the gut microbiome. When this balance is disrupted, the intestinal barrier can weaken and allow inflammatory signals to escalate, contributing to disease. Live biotherapeutics aim to restore microbial balance, strengthen the gut lining, and reduce inflammation. Early research in conditions like inflammatory bowel disease has shown that modifying the microbiome—through approaches such as fecal microbiota transplants or defined microbial consortia—can induce remission in some patients, although questions around long-term durability and safety remain.
This biology is increasingly relevant in oncology, particularly with immune checkpoint inhibitors (ICIs). These therapies work by activating T cells to attack tumors more aggressively, transforming treatment across multiple cancer types. However, this heightened immune activity can also damage healthy tissue. In the gastrointestinal tract, this can lead to immune checkpoint inhibitor-related enterocolitis (irEC), a potentially severe condition marked by diarrhea, abdominal pain, and bleeding. Approximately one quarter of U.S. patients receiving ICIs develop moderate to severe irEC.
Current treatment guidelines typically require pausing cancer therapy and initiating systemic immunosuppressive drugs such as high-dose steroids or biologics. While often effective, these interventions carry their own risks and may reduce the anti-tumor benefits of immunotherapy. This trade-off has created a clear unmet need for therapies that can control irEC without broadly suppressing the immune system.
Seres Therapeutics, Inc. (NASDAQ: MCRB) has positioned itself at this intersection of microbiome science and immunotherapy. The company previously developed VOWST, the first FDA-approved oral microbiome therapeutic for preventing recurrent Clostridioides difficile infection, later licensed to Nestlé Health Science. Its broader pipeline focuses on defined microbial consortia designed for targeted functions, including infection prevention and inflammation control.
One of its lead candidates, SER-155, is a multi-strain live biotherapeutic currently being evaluated for both infection prevention in transplant patients and treatment of irEC. Early data from an investigator-sponsored trial at Memorial Sloan Kettering Cancer Center offer an initial look at its potential in oncology supportive care.
The study enrolled 15 patients with Grade 2 or 3 irEC who had not yet received systemic immunosuppressive therapy. Patients underwent microbiome conditioning with oral vancomycin, followed by a 12-day course of SER-155. By Day 15, 80 percent of participants achieved the trial’s definition of clinical response—at least a one-grade improvement in diarrhea without steroids or biologics. Notably, two-thirds of responders improved by two grades or more.
Complete remission, defined as resolution of diarrhea without systemic immunosuppression, was observed in 33 percent of patients at Day 15. By Day 43, a subset of patients maintained their response, including two who remained in complete remission without additional immunosuppressive therapy. Others preserved clinical improvement but later received localized, non-systemic treatments.
Safety findings were encouraging. SER-155 was generally well tolerated, with no serious adverse events attributed to the therapy and no treatment-related bloodstream infections reported over the 43-day observation period.
Biomarker data provided additional support for the therapy’s mechanism of action. Most bacterial strains in SER-155 successfully engrafted in patients’ gastrointestinal tracts, with patterns consistent with prior studies. Markers of inflammation, such as fecal calprotectin, and indicators of intestinal barrier damage, such as fecal albumin, declined over time and showed statistically significant reductions by Day 43. These trends suggest that the therapy may help restore gut integrity and reduce inflammatory signaling—key drivers of irEC.
Seres is part of a broader wave of companies exploring microbiome-based therapies. The field includes approaches ranging from fecal transplants to engineered bacterial strains and rationally designed microbial consortia. Programs such as VE202 and FIN-524, along with efforts from companies like Rebiotix and Finch Therapeutics, reflect a shift toward more standardized, scalable alternatives to traditional transplant methods.
The significance lies less in any single product and more in the broader transition toward treating the microbiome as a druggable system. Live biotherapeutics could eventually sit alongside small molecules and biologics as a distinct therapeutic category, particularly in gastrointestinal and immune-mediated diseases.
The commercial outlook for SER-155 will depend on whether these early findings can be replicated in larger, controlled trials. If successful, the therapy could address a meaningful gap in oncology by allowing patients to remain on checkpoint inhibitors without the need for systemic immunosuppression. Given the multibillion-dollar scale of the immunotherapy market, even incremental improvements in managing side effects like irEC could carry significant clinical and financial implications.
Seres has indicated interest in partnering with checkpoint inhibitor manufacturers as development advances. For now, SER-155 represents an early but tangible example of how live biotherapeutics may move from experimental concept to practical application in cancer care.
